COVID-19

1. Clinical Overview

Summary

COVID-19 (Coronavirus Disease 2019) is a systemic viral illness caused by the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). First identified in Wuhan, China in December 2019, it rapidly evolved into a global pandemic that fundamentally transformed healthcare delivery, public health policy, and clinical medicine. [1,2]

The clinical spectrum of COVID-19 is extraordinarily diverse, ranging from completely asymptomatic infection (approximately 20-40% of cases) to fulminant Acute Respiratory Distress Syndrome (ARDS), multi-organ failure, and death. [3,4] The disease exhibits a biphasic pattern in severe cases, with an initial viral replication phase followed by a hyperinflammatory phase characterized by cytokine storm and immunothrombosis. [5]

Management has evolved substantially through rigorous clinical trials. While early antiviral therapy (e.g., nirmatrelvir-ritonavir/Paxlovid) can prevent progression in high-risk outpatients, the cornerstone of survival in severe hospitalized disease is immunomodulation through corticosteroids (dexamethasone) and IL-6 receptor antagonists (tocilizumab), combined with aggressive respiratory support including CPAP, prone positioning, and mechanical ventilation. [6,7,8] Vaccination has dramatically reduced mortality and severe disease burden globally. [9]

Key Facts

• Causative Agent: SARS-CoV-2, a positive-sense single-stranded RNA betacoronavirus with high phylogenetic similarity to SARS-CoV-1 (79%) and bat coronaviruses (96%). [10]

• Transmission: Primarily respiratory droplets and aerosols. Airborne transmission is significant, particularly in poorly ventilated indoor settings. Fomite transmission is possible but less common. [11,12]

• Receptor Binding: The viral Spike (S) protein binds with high affinity to ACE2 (Angiotensin-Converting Enzyme 2) receptors, which are abundantly expressed in type II alveolar pneumocytes, cardiac myocytes, vascular endothelium, renal tubular epithelium, and gastrointestinal enterocytes. [13,14]

• Incubation Period: Median 4-5 days (range 2-14 days). Delta variant: 4 days; Omicron: 2-3 days. [15]

• Viral Evolution: The virus has undergone significant antigenic drift:

  • "Alpha (B.1.1.7): Increased transmissibility (~50% more contagious)"
  • "Delta (B.1.617.2): Highest virulence, severe pneumonia, partial immune escape"
  • "Omicron (B.1.1.529 and sublineages): Extensive immune escape, upper airway tropism, generally milder disease due to reduced lower respiratory tract infection, but high transmissibility and reinfection rates [16,17]"

• Immunothrombosis: COVID-19 induces a unique prothrombotic state characterized by endothelial inflammation, complement activation, neutrophil extracellular traps (NETs), and microthrombi formation, leading to elevated rates of venous thromboembolism (VTE), pulmonary embolism (PE), and arterial thrombosis. [18,19]

• Long COVID (Post-Acute Sequelae of SARS-CoV-2 Infection, PASC): Persistent symptoms beyond 12 weeks, affecting approximately 10-20% of infected individuals. Common manifestations include fatigue, dyspnea, cognitive dysfunction ("brain fog"), post-exertional malaise, and dysautonomia (POTS). [20,21]

Clinical Pearls

Silent Hypoxia ("Happy Hypoxia"): A pathognomonic feature of COVID-19 pneumonia where patients exhibit profound hypoxemia (SpO2 70-85%) yet appear subjectively comfortable without proportionate dyspnea or tachypnea. This dissociation results from preserved lung compliance in early disease with severe ventilation-perfusion (V/Q) mismatch. Trust the pulse oximeter, not the patient's appearance. This phenomenon necessitates home pulse oximetry monitoring for at-risk patients. [22,23]

The Biphasic Illness Pattern: Many patients with severe COVID-19 demonstrate a characteristic "biphasic" trajectory: mild upper respiratory symptoms for 5-7 days, followed by sudden clinical deterioration around days 7-10 with fever recrudescence, hypoxemia, and rapid progression to ARDS. This transition marks the onset of the hyperinflammatory phase (cytokine storm), driven by dysregulated immune response with elevated IL-6, IL-1β, and TNF-α. [24,25]

Steroid Timing is Critical: Corticosteroids are contraindicated in the early viral replication phase (days 0-7) as they may enhance viral replication. Dexamethasone should be administered ONLY when patients require supplemental oxygen (SpO2 less than 94% on room air), indicating transition to the inflammatory phase. The RECOVERY trial definitively demonstrated mortality reduction in hypoxemic patients but potential harm in non-hypoxemic individuals. [6]

Proning in Non-Intubated Patients: Awake prone positioning (lying on stomach) for 12+ hours daily can improve oxygenation by 10-25% in non-intubated patients by optimizing V/Q matching in dorsal lung segments. This simple intervention may avert mechanical ventilation. [26]

D-Dimer as Prognostic Marker: Markedly elevated D-dimer (> 2000 ng/mL) on admission predicts severe disease, thrombotic complications, and mortality. Serial D-dimer monitoring guides anticoagulation escalation. [27,28]

---

2. Epidemiology

Global Burden

COVID-19 has caused over 7 million reported deaths globally as of 2024, with actual mortality likely substantially higher due to underreporting, particularly in low- and middle-income countries. [29,30] The pandemic has occurred in successive waves driven by viral evolution (emergence of variants of concern), seasonal factors, waning immunity, and varying public health interventions.

Incidence and Prevalence

• Pre-Vaccine Era (2020-2021): Attack rates ranged from 5-30% in various populations during major outbreaks
• Post-Vaccine Era (2022-present): Seroprevalence studies indicate > 90% of populations in many countries have evidence of prior infection or vaccination, though reinfections are common with Omicron variants [31]

Risk Factors for Severe Disease and Mortality

Non-Modifiable Risk Factors

1. Age: The single strongest predictor. Risk of hospitalization and death increases exponentially with age:

   • Age 50-64: 4-fold increased risk vs. 18-29
   • Age 65-74: 7-fold increased risk
   • Age ≥75: 12-fold increased risk [32,33]

2. Sex: Males have 1.5-2× higher risk of severe disease and death compared to females, likely due to hormonal, immunological, and behavioral factors. [34]

3. Ethnicity: BAME (Black, Asian, Minority Ethnic) populations in the UK and Hispanic/African American populations in the US experienced disproportionately higher mortality, attributed to structural inequalities, occupational exposures, comorbidity burden, and potential genetic factors (e.g., Neanderthal gene cluster on chromosome 3). [35,36]

Modifiable Risk Factors and Comorbidities

1. Obesity: BMI ≥30 kg/m² confers 1.5-2× increased risk of severe disease. BMI ≥40 (class III obesity) carries 3-4× risk. Mechanisms include ACE2 upregulation in adipose tissue, chronic inflammation, impaired respiratory mechanics, and immune dysfunction. [37,38]

2. Diabetes Mellitus: 2-3× increased risk of severe disease and mortality. Both Type 1 and Type 2 diabetes increase risk, with poorest outcomes in those with HbA1c > 9%. [39]

3. Cardiovascular Disease: Pre-existing heart disease (coronary artery disease, heart failure, cardiomyopathy) increases mortality risk 2-3×. [40]

4. Chronic Respiratory Disease: COPD, interstitial lung disease, and moderate-severe asthma increase risk. Interestingly, well-controlled asthma alone may not substantially increase risk. [41]

5. Chronic Kidney Disease: Stage 4-5 CKD and dialysis dependence significantly increase mortality risk. [42]

6. Immunosuppression:

   • Solid organ transplant recipients
   • Hematological malignancy
   • Primary immunodeficiency disorders
   • Immunosuppressive medications (high-dose corticosteroids, rituximab, chemotherapy) These groups have prolonged viral shedding, reduced vaccine responses, and increased mortality. [43,44]

7. Smoking: Current smoking increases risk of progression by approximately 1.8×. [45]

Vaccination Status

Full vaccination (primary series plus boosters) reduces risk of hospitalization by 70-90% and death by > 90%, even with Omicron variants, though efficacy wanes over time (particularly against infection). [46,47]

---

3. Pathophysiology

COVID-19 is a multi-system disease with complex pathophysiology involving direct viral cytopathic effects, dysregulated immune responses, and microvascular thrombosis. [48]

Molecular Virology

SARS-CoV-2 Structure:

• Enveloped RNA virus, ~30kb genome encoding 16 non-structural proteins (NSPs), 4 structural proteins (Spike, Envelope, Membrane, Nucleocapsid), and accessory proteins
• Spike (S) Protein: Contains receptor-binding domain (RBD) that binds ACE2; target of neutralizing antibodies and vaccines
• The S protein requires priming by host proteases (TMPRSS2, furin) for membrane fusion [49,50]

Viral Entry Mechanism:

1. Spike protein RBD binds ACE2 receptor
2. TMPRSS2 protease cleaves S protein (S1/S2 cleavage)
3. Membrane fusion and viral RNA release into cytoplasm
4. Viral RNA translation using host ribosomes
5. RNA replication via viral RNA-dependent RNA polymerase (RdRp)
6. Assembly of new virions in endoplasmic reticulum/Golgi
7. Release via exocytosis [51]

Phases of COVID-19 Illness

Phase I: Viral Replication (Days 0-7)

Pathophysiology:

• Viral invasion of respiratory epithelium (nasopharynx, conducting airways)
• Initial ACE2-mediated infection of type II pneumocytes
• Direct viral cytopathic effect causing epithelial cell death
• Interferon response (often delayed, contributing to disease severity)
• Viral RNA serves as PAMP (pathogen-associated molecular pattern) activating innate immunity

Clinical Manifestations:

• Fever, malaise, myalgia
• Dry cough, sore throat
• Anosmia/ageusia (olfactory epithelium infection)
• Laboratory: Lymphopenia, normal/mildly elevated CRP

Key Insight: Antiviral therapies (nirmatrelvir-ritonavir, remdesivir) are most effective during this phase. [52,53]

Phase II: Pulmonary Phase (Days 7-10)

Pathophysiology:

• Progressive alveolar damage with diffuse alveolar damage (DAD) pattern
• Type II pneumocyte destruction leading to surfactant deficiency
• Inflammatory infiltrate: Lymphocytes, macrophages, neutrophils
• Hyaline membrane formation
• Ventilation-perfusion (V/Q) mismatch:
  • "Shunt: Perfused but non-ventilated alveoli (blood bypasses gas exchange)"
  • "Dead space: Ventilated but hypoperfused areas (due to microthrombi)"
• Relative preservation of lung compliance early (distinguishing from typical ARDS)
• Hypoxic pulmonary vasoconstriction may be impaired, worsening V/Q mismatch [54,55]

Clinical Manifestations:

• Progressive dyspnea
• Hypoxemia (silent hypoxia phenomenon)
• Tachypnea
• Imaging: Bilateral ground-glass opacities
• Laboratory: Rising CRP, D-dimer, ferritin

Phase III: Hyperinflammatory Phase (Days 10+)

Pathophysiology - Cytokine Storm:

• Dysregulated host immune response with excessive pro-inflammatory cytokine release:
  • "IL-6: Key driver (target of tocilizumab/sarilumab)"
  • IL-1β, TNF-α, IL-8, IFN-γ
• Macrophage activation syndrome-like picture
• Systemic inflammation leads to:
  • Acute respiratory distress syndrome (ARDS)
  • Septic shock
  • Multi-organ dysfunction

Immunothrombosis:

• Endothelial dysfunction and endotheliitis
• Complement activation (alternative pathway)
• Platelet activation and aggregation
• Neutrophil extracellular traps (NETs) formation
• Tissue factor expression → coagulation cascade activation
• Microthrombi in pulmonary vasculature and other organs
• Elevated D-dimer, fibrinogen, Factor VIII
• Increased incidence of VTE, PE, arterial thrombosis, DIC [56,57,58]

Clinical Manifestations:

• ARDS: Bilateral infiltrates, PaO2/FiO2 less than 300, non-cardiogenic pulmonary edema
• Shock: Cytokine-mediated vasodilation, myocardial depression
• Thrombotic complications: PE, DVT, stroke, limb ischemia, myocardial infarction
• Acute kidney injury (25-50% of ICU patients): ATN, direct viral injury, microthrombi
• Cardiac injury: Myocarditis, stress cardiomyopathy, arrhythmias
• Neurological: Encephalopathy, stroke, Guillain-Barré syndrome
• Laboratory: Markedly elevated CRP (> 150 mg/L), ferritin (> 1000 μg/L), D-dimer (> 2000 ng/mL), troponin, LDH

Key Insight: Immunomodulation (dexamethasone, tocilizumab) and anticoagulation are critical during this phase. [6,7,59]

Organ-Specific Pathophysiology

Respiratory System

• Direct pneumocyte damage
• Surfactant dysfunction
• Pulmonary endothelial injury
• Organizing pneumonia pattern in some cases
• Long-term: Post-COVID pulmonary fibrosis in severe ARDS survivors [60]

Cardiovascular System

• Myocarditis (direct viral invasion, immune-mediated)
• Stress cardiomyopathy (Takotsubo)
• Coronary thrombosis and myocardial infarction
• Arrhythmias (atrial fibrillation, ventricular arrhythmias)
• Pericarditis [61,62]

Renal System

• Acute tubular necrosis (ATN) from hypoperfusion/shock
• Direct viral infection of proximal tubular cells (ACE2+)
• Glomerular microthrombi
• Rhabdomyolysis-associated AKI [63]

Neurological System

• Ischemic/hemorrhagic stroke (prothrombotic state)
• Encephalopathy (hypoxia, metabolic derangement, direct neuroinvasion)
• Anosmia/ageusia (olfactory epithelium/nerve involvement)
• Guillain-Barré syndrome (post-infectious immune-mediated)
• Critical illness neuropathy/myopathy [64,65]

Gastrointestinal System

• Direct ACE2-mediated intestinal epithelial infection
• Diarrhea, nausea, vomiting
• Elevated transaminases (hepatocellular injury)
• Pancreatic injury [66]

Immune Response

Innate Immunity:

• Pattern recognition receptors (TLR3, TLR7, RIG-I) detect viral RNA
• Type I and III interferon response (often delayed/impaired in severe COVID-19)
• NK cell and macrophage activation

Adaptive Immunity:

• Humoral: Neutralizing antibodies to Spike protein RBD; IgM peaks week 2, IgG peaks week 3-4 and persists for months-years
• Cellular: CD4+ T helper cells and CD8+ cytotoxic T cells; T cell responses may be more durable and cross-reactive to variants than antibody responses
• Memory B and T cells provide long-term immunity [67,68]

Immunopathology in Severe Disease:

• Lymphopenia (particularly CD4+ and CD8+ T cells)
• Delayed/impaired interferon response
• Excessive inflammatory monocyte-macrophage activation
• Neutrophilia and NETosis
• Complement dysregulation [69]

---

4. Clinical Presentation

Symptom Spectrum by Variant

The clinical presentation has evolved with viral variants:

Classic/Alpha/Delta Variants

Most Common Symptoms (in order of frequency):

1. Fever (70-90%)
2. Dry cough (60-80%)
3. Fatigue (40-60%)
4. Anosmia (loss of smell) and Ageusia (loss of taste) (40-60%) - highly specific features
5. Dyspnea (30-40%, more common in severe disease)
6. Myalgia (20-40%)
7. Headache (10-20%)
8. Sore throat (10-15%)

Omicron Variants (2022-present)

Shifted Symptom Profile:

1. Sore throat (very common)
2. Rhinorrhea/nasal congestion
3. Headache
4. Fatigue
5. Cough (may be productive)
6. Fever (less common than earlier variants)
7. Anosmia/ageusia (markedly reduced frequency, ~10-15%)

Clinical presentation now closely mimics common cold/upper respiratory tract infection, making clinical diagnosis challenging without testing. [70]

Disease Severity Classification

Asymptomatic/Presymptomatic

• Positive SARS-CoV-2 test without symptoms
• ~20-40% of infections
• Viral loads similar to symptomatic cases (can transmit)

Mild Disease (80% of symptomatic cases)

• Symptoms of upper respiratory tract infection ± fever
• No dyspnea or abnormal chest imaging
• SpO2 ≥94% on room air
• Management: Outpatient, supportive care, monitor for deterioration

Moderate Disease (15% of symptomatic cases)

• Evidence of lower respiratory tract infection (clinical or imaging)
• SpO2 90-94% on room air OR
• Respiratory rate 20-30/min
• Management: May require hospitalization, supplemental oxygen, monitoring

Severe Disease (5% of symptomatic cases)

• SpO2 less than 90% on room air OR
• Respiratory rate > 30/min OR
• PaO2/FiO2 less than 300 mmHg
• Management: Hospitalization, oxygen ± CPAP, dexamethasone, anticoagulation

Critical Disease (1-2% of symptomatic cases)

• Respiratory failure requiring mechanical ventilation OR
• Shock (requiring vasopressors) OR
• Multi-organ dysfunction requiring ICU care
• Mortality: 30-50% in mechanically ventilated patients

Extra-Pulmonary Manifestations

Gastrointestinal (10-20%)

• Diarrhea (most common)
• Nausea, vomiting
• Abdominal pain
• Anorexia
• May occur without respiratory symptoms [71]

Dermatological

• "COVID toes": Chilblain-like acral lesions (purplish, painful, self-limiting)
• Maculopapular rash
• Urticarial lesions
• Petechiae/purpura (thrombocytopenia, vasculitis) [72]

Neurological

• Central: Encephalopathy/delirium (common in elderly), encephalitis, stroke, seizures
• Peripheral: Guillain-Barré syndrome, other neuropathies
• Olfactory: Anosmia/ageusia (may persist for months) [73]

Cardiovascular

• Chest pain/pressure
• Palpitations
• Myocardial injury (elevated troponin)
• Acute coronary syndrome
• Myocarditis/pericarditis
• Arrhythmias [74]

Thromboembolic

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE) - occurs in 10-20% of hospitalized patients
• Arterial thrombosis (stroke, limb ischemia, mesenteric ischemia)
• Catheter-related thrombosis [75]

Paediatric-Specific Presentations

Most children have asymptomatic or mild disease. However:

Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) / MIS-C:

• Rare but serious post-infectious complication (2-6 weeks after acute infection)
• Resembles Kawasaki disease and toxic shock syndrome
• Features: Persistent fever, multi-system involvement (cardiac, GI, hematologic, mucocutaneous), shock
• Diagnosis: Fever + inflammation + multi-organ dysfunction + SARS-CoV-2 exposure
• Treatment: IVIG, aspirin, corticosteroids
• Generally good prognosis with prompt treatment [76,77]

Atypical Presentations

• Elderly: May present with delirium, falls, functional decline without typical respiratory symptoms
• Immunocompromised: May have prolonged viral replication (weeks-months), potential for variant emergence

---

5. Clinical Examination

General Appearance

• Assess work of breathing, distress level
• Conscious level (Alert / Confused / Drowsy)
• Position (tripod positioning suggests severe dyspnea)

Vital Signs - Critical Parameters

Temperature:

• Fever (> 38°C) common in acute phase
• Absence of fever does NOT exclude COVID-19

Respiratory Rate:

• Most sensitive early marker of deterioration
• Normal: 12-20/min
• Tachypnea (> 20/min) indicates pulmonary involvement

• 24/min: concerning

• 30/min: severe disease, consider ICU

Oxygen Saturation (SpO2):

• Gold standard measurement: Room air SpO2 at rest AND with exertion
• "Sit-to-Stand Desaturation Test": Measure baseline SpO2, perform 40 sit-to-stand repetitions, remeasure SpO2
  • ≥3% drop is abnormal
  • Identifies early pulmonary involvement when resting SpO2 normal [78]
• Target: ≥94% (≥88% if chronic respiratory disease with baseline hypoxia)
• Beware silent hypoxia: Patient may appear comfortable despite SpO2 75-85%

Heart Rate:

• Tachycardia (> 100 bpm): Sepsis, hypoxia, dehydration
• Relative bradycardia may occur

Blood Pressure:

• Hypotension (less than 90 systolic): Septic shock, cytokine storm

Respiratory Examination

Inspection:

• Use of accessory muscles
• Intercostal/subcostal recession
• Cyanosis (late sign)

Palpation:

• Chest expansion (often normal until late disease)

Percussion:

• Usually resonant (consolidation less common than typical bacterial pneumonia)

Auscultation:

• Early disease: Chest often CLEAR despite hypoxia and imaging abnormalities (ground-glass opacities don't produce crackles)
• Progressive disease: Fine inspiratory crackles, particularly bibasal
• Late/severe disease: Coarse crackles, bronchial breathing (consolidation)

Cardiovascular Examination

• Tachycardia
• Hypotension (shock)
• Elevated JVP (fluid overload, RV strain from PE)
• Peripheral edema
• Signs of DVT (leg swelling, tenderness)

Neurological Examination

• Conscious level (GCS)
• Confusion/delirium (particularly in elderly)
• Focal neurological deficits (stroke)
• Peripheral neuropathy signs (Guillain-Barré)

Abdominal Examination

• Tenderness (less common, but may indicate pancreatitis, hepatitis, mesenteric ischemia)
• Hepatomegaly (hepatitis)

Dermatological Examination

• Rash patterns
• COVID toes (acral chilblain-like lesions)
• Petechiae (thrombocytopenia, DIC)

---

6. Investigations

Diagnostic Testing for Acute Infection

RT-PCR (Reverse Transcriptase Polymerase Chain Reaction)

Gold Standard Diagnostic Test

• Specimen: Nasopharyngeal swab (preferred), oropharyngeal swab, combined nose-throat swab, saliva, BAL (in intubated patients)
• Sensitivity: 70-95% (depends on timing, specimen quality, viral load)
  • "Highest sensitivity: Days 3-7 of symptoms"
  • False negatives increase after day 10-14
• Specificity: > 99%
• Turnaround Time: 2-24 hours (laboratory-based)
• Advantages: High sensitivity and specificity, quantitative (Ct value)
• Ct (Cycle Threshold) Value: Lower Ct = higher viral load = more infectious [79]

Rapid Antigen Tests (Lateral Flow Tests, LFTs)

• Mechanism: Detect viral nucleocapsid or spike protein
• Sensitivity: 50-80% (lower than PCR, particularly in asymptomatic/low viral load)
• Specificity: 95-99%
• Turnaround Time: 15-30 minutes
• Use Case: Point-of-care testing, screening
• Limitation: False negatives common with low viral loads; positive results reliable, negative results should be confirmed with PCR if high suspicion [80]

Serology (Antibody Testing)

Not for Acute Diagnosis (antibodies appear 1-3 weeks after symptom onset)

• IgM: Appears ~7-14 days, peaks ~2-4 weeks, declines
• IgG: Appears ~10-21 days, persists for months-years
• Use Cases:
  • Retrospective diagnosis
  • Seroprevalence studies
  • Assessing vaccine response (not routinely recommended)

Laboratory Investigations in Hospitalized Patients

Hematology

Full Blood Count (FBC):

• Lymphopenia (less than 1.0 × 10⁹/L): Hallmark finding, present in 60-80% of cases
  • More severe lymphopenia correlates with worse outcomes
  • Affects CD4+ and CD8+ T cells predominantly
• Neutrophilia: Suggests bacterial co-infection or superinfection
• Thrombocytopenia (mild-moderate): Common in severe disease
• Eosinopenia: Often present

Inflammatory Markers

C-Reactive Protein (CRP):

• Elevated in > 60% of hospitalized patients
• CRP > 100 mg/L: Severe disease
• CRP > 150-200 mg/L: High risk of deterioration, consider tocilizumab
• Serial monitoring guides treatment escalation [81]

Ferritin:

• Acute phase reactant
• Markedly elevated (> 500-1000 μg/L) in severe disease/cytokine storm
• Predictor of mortality

Lactate Dehydrogenase (LDH):

• Elevated (marker of tissue damage)
• Correlates with disease severity

Procalcitonin (PCT):

• Usually normal/mildly elevated in pure COVID-19
• Elevated (> 0.25-0.5 ng/mL): Suggests bacterial co-infection/superinfection
• Guides antibiotic prescribing [82]

Coagulation Studies

D-Dimer:

• Elevated (> 500 ng/mL) in majority of hospitalized patients
• Markedly elevated (> 1000-2000 ng/mL): Predictor of severe disease, thrombotic complications, mortality
• Serial monitoring: Rising D-dimer indicates worsening coagulopathy, may warrant therapeutic anticoagulation
• Key Prognostic Marker [83]

PT/APTT, Fibrinogen:

• Usually normal or mildly prolonged
• Markedly abnormal suggests DIC (disseminated intravascular coagulation)

Biochemistry

Renal Function (U&E, Creatinine):

• Acute kidney injury (AKI) in 25-50% of ICU patients
• Rising creatinine indicates AKI (ATN, direct viral injury, microthrombi)

Liver Function Tests (LFTs):

• Transaminitis (ALT, AST elevation) common, usually mild
• Severe elevation suggests hepatitis, shock liver, drug-induced

Troponin:

• Elevated in 20-30% of hospitalized patients
• Indicates myocardial injury (myocarditis, ischemia, stress cardiomyopathy, demand ischemia)
• Strong predictor of mortality [84]

BNP/NT-proBNP:

• Elevated in heart failure, PE, myocarditis
• Helps differentiate cardiogenic vs non-cardiogenic pulmonary edema

Arterial Blood Gas (ABG)

Essential in Hypoxic Patients:

• PaO2: Assess severity of hypoxemia
• PaO2/FiO2 Ratio: Defines ARDS severity
  • "Mild ARDS: 200-300 mmHg"
  • "Moderate ARDS: 100-200 mmHg"
  • "Severe ARDS: less than 100 mmHg"
• PaCO2: Usually normal early (hyperventilation), rises late (fatigue, ARDS)
• pH: Respiratory alkalosis (early), metabolic acidosis (shock, lactic acidosis)
• Lactate: Elevated in shock/tissue hypoperfusion

Imaging

Chest X-Ray (CXR)

Typical Findings:

• Bilateral, peripheral, lower zone predominant airspace opacification
• Ground-glass opacities (difficult to appreciate on plain film)
• Consolidation (progressive disease)
• "Crazy paving" pattern (ground-glass with interlobular septal thickening)
• Usually bilateral, but can be unilateral early

Progression:

• Normal CXR possible in early/mild disease
• Abnormalities peak around days 10-12
• Resolution over weeks-months

Key Use: Baseline assessment, monitoring progression, excluding complications (pneumothorax, pleural effusion) [85]

CT Chest (High-Resolution CT, HRCT)

More Sensitive than CXR

Classic Findings:

• Bilateral, peripheral, subpleural ground-glass opacities (GGOs)
• Multifocal distribution
• Posterior and lower lobe predominance
• Consolidation (progressive disease)
• Crazy-paving pattern
• Septal thickening
• Halo sign

Temporal Evolution:

• 0-4 days: Normal or minimal GGO
• 5-8 days: Progressive GGO, consolidation
• 9-13 days: Peak abnormalities, consolidation predominates
• 14+ days: Gradual resolution, organizing pneumonia pattern possible

CT Severity Scoring: Quantifies extent of lung involvement (prognostic)

Indications:

• Not routine (CXR sufficient for most)
• Consider for: Diagnostic uncertainty, suspected complications (PE with CTPA), ICU patients

CTPA (CT Pulmonary Angiogram): High incidence of PE in COVID-19; low threshold for CTPA if D-dimer elevated + clinical suspicion [86]

Lung Ultrasound (Point-of-Care)

• B-lines (interstitial syndrome)
• Consolidation
• Pleural line abnormalities
• Advantages: Bedside, no radiation, serial monitoring
• Requires expertise [87]

Microbiological Investigations

Bacterial Co-Infection Screen (if procalcitonin elevated or clinical suspicion):

• Blood cultures
• Sputum culture (if productive cough)
• Urinary pneumococcal and legionella antigens

Other Respiratory Viruses:

• Influenza PCR (co-infection possible)
• Respiratory viral panel

---

7. Management

The management of COVID-19 is stratified by disease severity and has evolved substantially based on high-quality RCT evidence, particularly from the UK RECOVERY trial. [6]

Risk Stratification and Triage

Outpatient Management (Mild Disease):

• SpO2 ≥94% on room air
• No risk factors for severe disease OR low-risk with close monitoring

Hospital Admission Criteria:

• SpO2 less than 94% on room air
• Respiratory rate > 24/min
• Clinical evidence of severe pneumonia
• Risk factors + clinical concern for deterioration
• Social factors (inability to self-care, lack of monitoring)

ICU Admission Criteria:

• Refractory hypoxemia despite high-flow oxygen/CPAP
• Requiring mechanical ventilation
• Shock requiring vasopressors
• Multi-organ failure

Management Algorithm

          CONFIRMED COVID-19
                  ↓
         ASSESS OXYGENATION
                  ↓
    ┌─────────────┴─────────────┐
SpO2 ≥94%                    SpO2 less than 94%
(Room Air)                   (HYPOXIC)
    ↓                             ↓
MILD-MODERATE                 SEVERE
    ↓                             ↓
OUTPATIENT                   ADMIT HOSPITAL
    │                             │
    ├─ Pulse oximetry         ┌───┴────┐
    │  monitoring             │        │
    │                      OXYGEN  PHARMACOTHERAPY
    ├─ Safety netting       (Target    │
    │  advice               94-98%)    ├─ Dexamethasone 6mg
    │                         │        │  OD x 10 days
    └─ Antiviral if          ├─ CPAP  │
       high-risk:             │  if    ├─ Tocilizumab if
       • Paxlovid             │  fail  │  CRP> 75 + O2 needs
       • Within 5 days        │        │  escalating
                              ├─ Prone │
                              │  position├─ Therapeutic
                              │        │  anticoagulation
                              └─ Intubate │  if indicated
                                 if fail │
                                         └─ VTE prophylaxis
                                            (all patients)

Respiratory Support - Stepwise Escalation

1. Supplemental Oxygen

Target Saturations:

• Standard patients: SpO2 94-98%
• Risk of hypercapnic respiratory failure (COPD, obesity hypoventilation): SpO2 88-92%

Delivery Systems:

• Nasal cannulae: 1-6 L/min (FiO2 ~24-40%)
• Simple face mask: 5-10 L/min
• Venturi mask: Controlled FiO2 (24%, 28%, 35%, 40%)
• Non-rebreather mask with reservoir: 10-15 L/min (FiO2 60-90%)
• High-flow nasal oxygen (HFNO): Up to 60 L/min, FiO2 up to 100%

2. CPAP (Continuous Positive Airway Pressure)

Mechanism:

• Positive pressure maintains alveolar recruitment
• Reduces work of breathing
• Improves oxygenation

Evidence:

• RECOVERY-RS trial: CPAP reduced intubation/mortality vs standard oxygen in hypoxemic COVID-19 pneumonia [88]

Indications:

• Persistent hypoxemia despite high-flow oxygen (e.g., requiring > 40% FiO2 to maintain SpO2 > 90%)
• Respiratory rate > 25-30/min
• Patient alert and cooperative

Settings: Typically 5-10 cmH2O PEEP, FiO2 titrated to target SpO2

Contraindications:

• Reduced consciousness (GCS less than 12)
• Inability to protect airway
• Facial trauma
• Undrained pneumothorax
• Severe upper GI bleeding
• Hemodynamic instability

3. Awake Prone Positioning

Mechanism:

• Redistributes lung perfusion to better-ventilated dorsal lung segments
• Improves V/Q matching
• Recruits collapsed posterior alveoli

Evidence:

• Meta-analyses show improved oxygenation and potential reduction in intubation rates [26]

Protocol:

• Target ≥12 hours per day in prone position
• Cycle through positions: Prone → Right lateral → Supine → Left lateral
• 30-120 minutes per position
• Monitor comfort and pressure areas

Efficacy: Can improve SpO2 by 10-25% in responders

Suitable for: Non-intubated patients on standard oxygen, HFNO, or CPAP

4. Mechanical Ventilation

Indications:

• Refractory hypoxemia (PaO2 less than 60 mmHg on FiO2 > 60%)
• Respiratory rate > 35/min with signs of fatigue
• Altered mental status due to hypercapnia/hypoxia
• Hemodynamic instability

Strategy - Lung-Protective Ventilation:

• Low tidal volume: 4-6 mL/kg ideal body weight
• Plateau pressure less than 30 cmH2O
• PEEP optimization (typically 8-15 cmH2O)
• Permissive hypercapnia (pH > 7.20)
• FiO2 titrated to SpO2 88-92% (PaO2 55-80 mmHg)

Prone Positioning (Intubated Patients):

• ≥12-16 hours daily
• Proven mortality benefit in moderate-severe ARDS [89]

Rescue Therapies (refractory hypoxemia):

• Recruitment maneuvers
• Higher PEEP
• Neuromuscular blockade
• Inhaled pulmonary vasodilators (nitric oxide, prostacyclin)
• ECMO (extracorporeal membrane oxygenation) - selected patients

Prognosis: Mortality in mechanically ventilated COVID-19 patients: 30-50%

Pharmacotherapy - Evidence-Based

1. Corticosteroids - CORNERSTONE of Severe COVID-19 Treatment

Dexamethasone 6 mg once daily (PO or IV) for 10 days (or until discharge)

Evidence - RECOVERY Trial [6]:

• Largest RCT in COVID-19 (> 6000 patients)
• Mortality Reduction:
  • "Mechanical ventilation: 29% reduction (41% → 29%)"
  • "Oxygen (not ventilated): 18% reduction (25% → 20%)"
  • "No oxygen: NO BENEFIT (potential harm)"
• Number Needed to Treat: 8 for ventilated patients

Mechanism: Suppresses dysregulated inflammatory response (cytokine storm), reduces ARDS progression

Indications: Patients requiring supplemental oxygen (SpO2 less than 94% on room air)

Contraindications: Bacterial/fungal sepsis (use cautiously with antimicrobial cover)

Alternatives (if dexamethasone unavailable):

• Hydrocortisone 50 mg IV QDS (equivalent)
• Prednisone 40 mg OD
• Methylprednisolone 32 mg OD

Key Principle: Do NOT use in early viral phase (non-hypoxemic patients) - may increase viral replication

2. IL-6 Receptor Antagonists

Tocilizumab 8 mg/kg IV (max 800 mg) × 1-2 doses OR Sarilumab 400 mg IV × 1 dose

Evidence - RECOVERY Trial [7]:

• Reduced mortality when added to dexamethasone in hypoxemic patients
• Mortality: 29% → 26% (absolute reduction 3%)
• Reduced progression to mechanical ventilation/death

Indications:

• Rapidly increasing oxygen requirements DESPITE dexamethasone
• CRP > 75 mg/L (indicates ongoing inflammation)
• Within 48 hours of ICU admission

Mechanism: Blocks IL-6 receptor, dampening cytokine storm

Monitoring: Risk of secondary infections, hepatotoxicity, neutropenia

3. Anticoagulation

VTE Prophylaxis - ALL hospitalized patients:

Standard Dose:

• Enoxaparin 40 mg SC once daily (20 mg if eGFR 15-30)
• Dalteparin 5000 units SC once daily
• Continue until discharge + 7-14 days post-discharge in high-risk patients

Rationale: High thrombosis risk due to immunothrombosis, immobility, inflammation [90]

Therapeutic Anticoagulation:

Indications:

• Confirmed VTE (DVT, PE)
• High clinical suspicion of VTE
• Markedly elevated D-dimer (> 3000-5000 ng/mL) with clinical deterioration (controversial, limited evidence)

Dosing:

• Enoxaparin 1 mg/kg SC twice daily
• Unfractionated heparin IV (aPTT-guided)

Note: Large RCT (ATTACC, REMAP-CAP) showed therapeutic anticoagulation NOT beneficial (and potentially harmful) in ICU patients; benefit possible in non-critically ill [91]

4. Antiviral Therapies

A. Nirmatrelvir-Ritonavir (Paxlovid) - FIRST-LINE OUTPATIENT ANTIVIRAL

Dosing: Nirmatrelvir 300 mg + Ritonavir 100 mg PO twice daily × 5 days

Evidence - EPIC-HR Trial [92]:

• 89% reduction in hospitalization/death in high-risk unvaccinated adults
• Must start within 5 days of symptom onset

Indications:

• Non-hospitalized patients with mild-moderate COVID-19
• High risk of progression (age ≥60, comorbidities, immunosuppression, unvaccinated)
• Within 5 days of symptom onset

Mechanism: Nirmatrelvir inhibits SARS-CoV-2 main protease (Mpro); ritonavir boosts nirmatrelvir levels via CYP3A4 inhibition

Drug Interactions: Ritonavir is potent CYP3A4 inhibitor - MANY interactions (statins, immunosuppressants, anticoagulants, calcium channel blockers, etc.) - CHECK INTERACTIONS

Contraindications: Severe renal/hepatic impairment, multiple drug interactions

B. Remdesivir

Dosing: 200 mg IV on day 1, then 100 mg IV daily × 4 days (total 5 days)

Evidence:

• Modest benefit in reducing time to recovery (15 → 10 days) in hospitalized patients requiring oxygen
• No mortality benefit
• Greater benefit if started early (less than 10 days of symptoms)

Indications:

• Hospitalized patients requiring oxygen (not mechanical ventilation)
• Early in disease course
• Not widely used in UK (RECOVERY trial showed no benefit); more common in US

Mechanism: Nucleotide analogue, inhibits viral RNA-dependent RNA polymerase [93]

C. Molnupiravir

Dosing: 800 mg PO twice daily × 5 days

Evidence: Modest reduction in hospitalization (30%) in high-risk patients; less effective than Paxlovid

Indications: Alternative to Paxlovid if contraindications/interactions

Mechanism: Nucleoside analogue, causes viral mutagenesis

Contraindications: Pregnancy (theoretical mutagenesis risk)

5. Monoclonal Antibodies - Limited Current Use

Neutralizing monoclonal antibodies (e.g., sotrovimab, casirivimab-imdevimab) were effective against earlier variants but have reduced/no activity against current Omicron sublineages due to Spike protein mutations. Use has been largely discontinued except for specific immunocompromised patients unable to mount immune response. [94]

6. Antibiotics - NOT ROUTINE

Bacterial Co-Infection/Superinfection:

• Rare at presentation (less than 5%)
• More common in ICU patients, mechanically ventilated patients
• Suspect if: Procalcitonin elevated, purulent sputum, lobar consolidation, clinical deterioration

Empiric Antibiotics (if suspected):

• Co-amoxiclav 1.2 g IV TDS OR
• Doxycycline 100 mg BD (atypical cover)
• Follow local CAP guidelines

DO NOT routinely prescribe antibiotics for COVID-19 - RECOVERY trial showed no benefit of azithromycin [95]

Supportive Care

Fluid Management:

• Conservative fluid strategy in ARDS (avoid fluid overload)
• Euvolemia target

Nutrition:

• Early enteral feeding
• High protein requirements in critical illness

Prophylaxis:

• Stress ulcer prophylaxis (PPI) if mechanically ventilated
• VTE prophylaxis (discussed above)

Monitoring:

• Continuous pulse oximetry (hypoxic patients)
• Cardiac monitoring (arrhythmia risk)
• Fluid balance
• Early warning scores (NEWS2)

Escalation Planning

Early goals-of-care discussions:

• Ceiling of treatment
• Resuscitation status (DNACPR)
• ICU appropriateness
• Patient values and preferences

Infection Prevention and Control

In Hospital:

• Airborne precautions (FFP3/N95 masks for aerosol-generating procedures)
• Droplet and contact precautions
• Single room isolation (negative pressure if available)
• PPE: Gown, gloves, surgical mask (FFP3 for AGPs)

AGPs (Aerosol-Generating Procedures):

• Intubation, extubation
• Bronchoscopy
• NIV/CPAP (debated)
• Nebulization

---

8. Vaccination

COVID-19 vaccines have been the most impactful public health intervention, preventing millions of deaths globally. [96]

Vaccine Platforms

1. mRNA Vaccines

BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna)

Mechanism:

• Lipid nanoparticle delivers mRNA encoding SARS-CoV-2 Spike protein
• Host ribosomes translate mRNA → Spike protein production
• Spike protein presented on MHC → B and T cell activation
• Neutralizing antibodies + cellular immunity

Efficacy (Original Trials, Pre-Omicron):

• 95% efficacy against symptomatic infection

• 90% against hospitalization/death

Efficacy (Omicron Era):

• 30-50% against infection (wanes rapidly)
• 70-90% against hospitalization/death (durable)

Dosing: 2-dose primary series (3-4 weeks apart) + boosters

2. Viral Vector Vaccines

ChAdOx1 (Oxford-AstraZeneca), Ad26.COV2.S (Janssen)

Mechanism:

• Replication-deficient adenovirus vector (chimpanzee adenovirus for AstraZeneca) carrying Spike gene
• Vector infects cells → Spike expression → immune response

Efficacy: 60-80% against symptomatic disease (earlier variants)

Rare Adverse Event: Vaccine-Induced Thrombotic Thrombocytopenia (VITT) - 1 in 50,000-100,000 doses; presents with thrombosis + thrombocytopenia 5-30 days post-vaccination; mechanism similar to heparin-induced thrombocytopenia (HIT) [97]

3. Protein Subunit Vaccines

NVX-CoV2373 (Novavax)

Mechanism: Recombinant Spike protein nanoparticles + adjuvant → immune response

Efficacy: ~90% against symptomatic disease

Booster Doses

Waning immunity (particularly neutralizing antibody titers) necessitates booster doses:

• Third dose (1st booster): 3-6 months after primary series
• Fourth dose (2nd booster): High-risk groups, elderly
• Bivalent boosters: Target both ancestral strain and Omicron variants

Vaccine Effectiveness

Against Infection: Moderate, wanes significantly by 3-6 months (especially Omicron)

Against Severe Disease/Hospitalization: High (70-90%), more durable

Against Death: Very high (> 90%), most durable

Key Message: Vaccination prevents severe disease and death, even if breakthrough infections occur.

Special Populations

Immunocompromised:

• 3-dose primary series (closer spacing)
• Additional boosters
• Reduced vaccine efficacy; may require prophylactic monoclonal antibodies

Pregnancy:

• Vaccination recommended (all trimesters)
• Protects mother and provides passive immunity to infant
• No safety concerns identified [98]

Children:

• Vaccines approved down to age 6 months (varies by country)
• Lower disease severity in children, but vaccination reduces transmission and prevents rare severe complications (PIMS-TS)

---

9. Complications

Acute Complications

1. Acute Respiratory Distress Syndrome (ARDS)

• Most common severe complication
• Bilateral pulmonary infiltrates, hypoxemia (PaO2/FiO2 less than 300), non-cardiogenic
• Requires mechanical ventilation
• High mortality (30-50%)
• Survivors may develop pulmonary fibrosis [99]

2. Thromboembolic Complications

Venous Thromboembolism:

• DVT: 10-15% of hospitalized patients
• PE: 10-20% of hospitalized patients, up to 30% of ICU patients
• Mechanism: Immunothrombosis, endothelial injury, hypercoagulability

Arterial Thrombosis:

• Stroke (ischemic): Increased risk, particularly in younger patients
• Myocardial infarction
• Limb ischemia, mesenteric ischemia

Management: Therapeutic anticoagulation for confirmed VTE; prophylactic anticoagulation for all hospitalized patients [100]

3. Cardiovascular Complications

Myocarditis/Myocardial Injury:

• Elevated troponin in 20-30% of hospitalized patients
• Direct viral invasion, immune-mediated injury, cytokine-mediated
• Arrhythmias (atrial fibrillation, ventricular arrhythmias)
• Cardiogenic shock

Stress Cardiomyopathy (Takotsubo)

Pericarditis/Pericardial Effusion

4. Acute Kidney Injury

• 25-50% of ICU patients
• Mechanisms: ATN (ischemia, nephrotoxins), direct viral injury, glomerular microthrombi, rhabdomyolysis
• May require renal replacement therapy
• Increased mortality

5. Neurological Complications

Central Nervous System:

• Encephalopathy/delirium (common in elderly)
• Encephalitis (rare)
• Ischemic stroke
• Hemorrhagic stroke
• Posterior reversible encephalopathy syndrome (PRES)
• Seizures

Peripheral Nervous System:

• Guillain-Barré syndrome
• Critical illness polyneuropathy/myopathy

6. Secondary Infections

Bacterial:

• Ventilator-associated pneumonia (VAP)
• Catheter-related bloodstream infections
• Common organisms: Staph aureus, Pseudomonas, Klebsiella

Fungal:

• Invasive pulmonary aspergillosis (COVID-19-associated pulmonary aspergillosis, CAPA)
• Candida bloodstream infections
• Mucormycosis (particularly in patients receiving corticosteroids, more common in India)

7. Multi-Organ Dysfunction Syndrome

• Combination of respiratory, cardiovascular, renal, hepatic, hematological failure
• Cytokine storm-mediated
• High mortality (> 50%)

Long-Term Complications - Long COVID (PASC)

Definition: Symptoms persisting > 12 weeks after acute infection, not explained by alternative diagnosis

Prevalence: ~10-20% of infected individuals; higher in hospitalized patients, females, those with multiple comorbidities [101]

Common Long COVID Symptoms

Constitutional:

• Profound fatigue (most common)
• Post-exertional malaise
• Fever, malaise

Respiratory:

• Dyspnea
• Chronic cough
• Chest tightness

Cardiovascular:

• Palpitations
• Chest pain
• Postural orthostatic tachycardia syndrome (POTS)

Neurological:

• Cognitive dysfunction ("brain fog") - impaired concentration, memory problems
• Headache
• Dizziness
• Peripheral neuropathy
• Persistent anosmia/dysgeusia

Psychological:

• Anxiety
• Depression
• Post-traumatic stress disorder (PTSD)
• Sleep disturbances

Musculoskeletal:

• Myalgia
• Arthralgia

Pathophysiology of Long COVID (Proposed Mechanisms)

1. Viral persistence: Low-level viral reservoirs in tissues
2. Immune dysregulation: Ongoing inflammation, autoantibody formation
3. Microvascular thrombosis: Endothelial dysfunction, microclots
4. Autonomic dysfunction: Dysautonomia (POTS)
5. Mitochondrial dysfunction: Impaired cellular energy production
6. Neuroinflammation: CNS inflammation, microglial activation [102]

Management of Long COVID

No Specific Cure - Management is symptomatic and rehabilitative

Multi-disciplinary Approach:

• Long COVID clinics
• Respiratory rehabilitation
• Cardiac rehabilitation
• Neuropsychological support
• Occupational therapy
• Pacing strategies (avoid post-exertional malaise)

Investigations:

• Chest X-ray (exclude structural lung disease)
• Spirometry (exclude restrictive/obstructive defects)
• Echocardiogram (if cardiac symptoms)
• Cognitive assessment
• Rule out alternative diagnoses (anemia, thyroid dysfunction, vitamin deficiencies)

Emerging Therapies (under investigation):

• Anticoagulation trials
• Anti-inflammatory therapies
• Antiviral therapies

---

10. Prognosis and Outcomes

Mortality

Overall Infection Fatality Rate (IFR):

• Pre-vaccine era: ~0.5-1% (highly age-dependent)
• Post-vaccine era: ~0.1-0.3%

Age-Stratified Mortality:

• 0-49 years: less than 0.1%
• 50-64 years: ~0.5-1%
• 65-74 years: ~3-5%
• ≥75 years: ~10-20%

Hospitalized Patients: 15-20% mortality (varies by age, comorbidities, vaccination status)

ICU/Mechanically Ventilated Patients: 30-50% mortality

Prognostic Factors

Poor Prognostic Indicators:

• Advanced age (> 65 years)
• Male sex
• Obesity (BMI > 30)
• Diabetes
• Cardiovascular disease
• Chronic kidney disease
• Immunosuppression
• Unvaccinated status
• Elevated inflammatory markers: CRP > 150 mg/L, D-dimer > 2000 ng/mL, ferritin > 1000 μg/L
• Lymphopenia less than 0.5 × 10⁹/L
• Elevated troponin
• High viral load (low Ct value)
• Requirement for mechanical ventilation

Prognostic Scores:

• 4C Mortality Score (Age, Sex, Comorbidities, Respiratory rate, SpO2, GCS, Urea, CRP)
• Accurately predicts in-hospital mortality

Recovery

Mild Disease: Full recovery in 1-2 weeks

Moderate-Severe Disease: Recovery over 3-6 weeks

Critical Disease: Prolonged ICU stay (weeks), prolonged rehabilitation, risk of long-term complications:

• Post-ICU syndrome
• Pulmonary fibrosis (post-ARDS)
• Cognitive impairment
• Physical deconditioning

Long COVID: Persistent symptoms in 10-20%, may last months-years

---

11. Prevention

Non-Pharmaceutical Interventions (NPIs)

Individual Level:

• Hand hygiene
• Respiratory etiquette (cough into elbow)
• Face masks (reduce transmission by 50-70% in community settings)
• Physical distancing (≥2 meters)
• Avoid crowded, poorly-ventilated indoor settings

Community Level:

• Ventilation improvements (indoor air quality)
• Testing and isolation of cases
• Contact tracing and quarantine

Population Level:

• Lockdowns (reduce transmission but significant societal costs)
• School closures
• Travel restrictions

Vaccination

Primary Prevention: Most effective intervention, prevents severe disease and death

Post-Exposure Prophylaxis

Previously Used (Limited Current Use):

• Monoclonal antibodies (evusheld) for immunocompromised - now ineffective against current variants
• No current effective post-exposure prophylaxis for most individuals

---

12. Special Populations

Pregnancy

Risks:

• Increased risk of severe disease in pregnancy (particularly third trimester)
• Increased risk of preterm delivery, stillbirth, maternal mortality
• Risk highest in unvaccinated

Management:

• Vaccination strongly recommended
• If infected: Close monitoring, low threshold for admission
• Treatment: Dexamethasone safe in pregnancy; most antivirals safe

Immunocompromised Patients

Characteristics:

• Prolonged viral shedding (weeks-months)
• Higher risk of severe disease and mortality
• Reduced vaccine efficacy
• Potential source of variant emergence (chronic infection with immune pressure)

Management:

• Extended primary vaccination course (3-4 doses)
• Additional boosters
• Early antiviral therapy (Paxlovid)
• Monoclonal antibodies (if active against circulating variant)
• Therapeutic drug monitoring of immunosuppressants (drug interactions)

Children and Adolescents

Generally Mild Disease, but:

• PIMS-TS (rare but serious)
• Long COVID can occur
• Vaccination recommended (benefits outweigh risks)

---

13. Evidence and Guidelines

Key International Guidelines

Landmark Trials

1. RECOVERY Trial (UK) - Most Important COVID-19 Trial

Design: Massive adaptive, open-label RCT in hospitalized patients

Key Findings:

Dexamethasone [6]:

• 6424 patients randomized to dexamethasone vs usual care
• Mortality Reduction:
  • "Mechanical ventilation: 29% (41% → 29%)"
  • "Oxygen only: 18% (25% → 20%)"
  • "No oxygen: NO BENEFIT (22% → 17%, not significant)"
• Conclusion: Dexamethasone 6 mg daily × 10 days reduces mortality in hypoxemic COVID-19 patients

Tocilizumab [7]:

• Added to dexamethasone in hypoxemic patients
• Reduced mortality: 33% → 29%
• Reduced progression to mechanical ventilation/death

Azithromycin [95]:

• NO BENEFIT on mortality, hospital stay, or ventilation
• Do NOT routinely use

Hydroxychloroquine:

• NO BENEFIT on mortality
• Stopped early for futility

Convalescent Plasma:

• NO BENEFIT on mortality

Colchicine:

• NO BENEFIT on mortality

2. EPIC-HR Trial - Paxlovid [92]

• High-risk unvaccinated outpatients with mild-moderate COVID-19
• Nirmatrelvir-ritonavir vs placebo within 5 days of symptoms
• 89% reduction in hospitalization/death
• Established Paxlovid as first-line outpatient antiviral

3. ACTIV-4a, REMAP-CAP, ATTACC - Anticoagulation [91]

• Therapeutic vs prophylactic anticoagulation in hospitalized patients
• Non-ICU patients: Possible benefit of therapeutic anticoagulation
• ICU patients: NO BENEFIT (potential harm)
• Conclusion: Prophylactic anticoagulation for all; therapeutic only for confirmed VTE

4. RECOVERY-RS - Respiratory Support [88]

• CPAP vs HFNO vs conventional oxygen
• CPAP reduced intubation/mortality vs conventional oxygen

5. Vaccine Efficacy Trials

• Pfizer-BioNTech (BNT162b2): 95% efficacy against symptomatic COVID-19
• Moderna (mRNA-1273): 94% efficacy
• AstraZeneca (ChAdOx1): 70% efficacy
• Real-world effectiveness confirms high protection against severe disease/death

---

14. Patient and Layperson Explanation

What causes COVID-19?

COVID-19 is caused by a virus called SARS-CoV-2. It spreads when an infected person coughs, sneezes, or talks, releasing tiny droplets containing the virus. When you breathe in these droplets or touch a contaminated surface and then touch your face, the virus can enter your body through your nose, mouth, or eyes.

What are the symptoms?

Most people have mild symptoms like a fever, cough, sore throat, and tiredness - similar to a cold or flu. Some people lose their sense of smell or taste. In severe cases, COVID-19 can cause difficulty breathing and pneumonia (lung infection), which may require hospital treatment.

When should I seek medical help?

Seek urgent medical attention if you have:

• Difficulty breathing or severe shortness of breath
• Chest pain or pressure
• Confusion or inability to wake up
• Bluish lips or face
• Oxygen levels below 94% (if you have a pulse oximeter)

What is the treatment?

For mild illness at home:

• Rest, drink plenty of fluids
• Paracetamol or ibuprofen for fever and aches
• Monitor your oxygen levels if you have a pulse oximeter
• If you're at high risk, your doctor may prescribe an antiviral medication (Paxlovid) to take within the first 5 days

For severe illness in hospital:

• Oxygen therapy to help you breathe
• A steroid medicine (dexamethasone) to reduce inflammation in your lungs
• Blood thinning injections to prevent blood clots
• In very severe cases, a breathing machine (ventilator)

Why do I need to lie on my stomach (proning)?

When your lungs are infected, lying on your back can cause fluid to pool in the lower parts of your lungs, making breathing harder. Lying on your stomach ("prone positioning") helps distribute the fluid more evenly and allows the back parts of your lungs (which are bigger) to work better. This can improve your oxygen levels and help you avoid needing a ventilator.

What is the cytokine storm?

Around day 7-10 of illness, some people's immune systems overreact, releasing too many inflammatory chemicals called cytokines. This "cytokine storm" can damage the lungs and other organs. This is when steroid medicines like dexamethasone are most helpful - they calm down the overactive immune system.

What is Long COVID?

Some people continue to have symptoms for weeks or months after recovering from the initial infection. Common symptoms include extreme tiredness, breathlessness, difficulty concentrating ("brain fog"), and a racing heart. We're still learning about Long COVID, but pacing yourself (not overdoing activities) and gradual rehabilitation can help. If you have persistent symptoms, speak to your doctor.

How can I protect myself and others?

1. Get vaccinated - vaccines dramatically reduce your risk of severe illness and death
2. Wear a mask in crowded indoor spaces
3. Wash your hands regularly with soap and water
4. Stay home if you're sick
5. Improve ventilation - open windows when indoors with others
6. Keep your distance from others when possible, especially if unwell

Is the vaccine safe?

Yes. COVID-19 vaccines have been given to billions of people worldwide and are very safe. Serious side effects are extremely rare. The vaccines are highly effective at preventing severe disease, hospitalization, and death. Common side effects (sore arm, tiredness, mild fever) are temporary and show your immune system is responding.

---

15. Examination Focus

Common Exam Questions

Clinical Scenarios

1. Medicine/Acute Care

Question: A 65-year-old man with type 2 diabetes presents to the Emergency Department with 7 days of cough and fever. He is tachypneic (RR 28/min) with SpO2 90% on room air. COVID-19 PCR is positive. CRP 180 mg/L, D-dimer 1800 ng/mL, lymphocyte count 0.6 × 10⁹/L. What is your immediate management?

Answer:

1. Oxygen therapy - target SpO2 94-98%
2. Dexamethasone 6 mg OD × 10 days (hypoxemic patient)
3. Prophylactic anticoagulation - Enoxaparin 40 mg SC daily
4. Monitor for deterioration - escalate to CPAP/HDU if oxygen requirements increase
5. Consider tocilizumab if oxygen needs escalate despite dexamethasone
6. Supportive care - fluids, nutrition
7. Do NOT routinely give antibiotics (procalcitonin normal)

2. Pharmacology

Question: What is the mechanism of action of tocilizumab in COVID-19?

Answer: Tocilizumab is a monoclonal antibody that blocks the IL-6 receptor. IL-6 is a key pro-inflammatory cytokine elevated in the hyperinflammatory phase of COVID-19 (cytokine storm). By blocking IL-6 signaling, tocilizumab dampens the excessive inflammatory response that causes ARDS and multi-organ dysfunction. It is used in patients with escalating oxygen requirements despite dexamethasone, typically when CRP > 75 mg/L.

3. Pathology

Question: What are the characteristic histopathological findings in the lungs of patients who died from severe COVID-19?

Answer:

• Diffuse alveolar damage (DAD): Classic ARDS pattern
  • "Exudative phase: Hyaline membranes, alveolar edema, inflammatory infiltrate"
  • "Proliferative phase: Type II pneumocyte hyperplasia, fibroblast proliferation"
  • "Fibrotic phase: Organizing pneumonia, fibrosis (in survivors)"
• Microthrombi: Fibrin thrombi in small pulmonary vessels (immunothrombosis)
• Inflammatory infiltrate: Lymphocytes, macrophages, neutrophils
• Endothelial injury and endotheliitis
• Viral cytopathic effect: Multinucleated syncytial cells in some cases

4. Radiology

Question: Describe the typical chest X-ray findings in COVID-19 pneumonia.

Answer:

• Bilateral, peripheral, lower-zone predominant airspace opacification
• Ground-glass opacities (difficult to appreciate on plain film; better seen on CT)
• Patchy consolidation (progressive disease)
• Relative sparing of upper lobes and central areas (early disease)
• Progression pattern: Normal → ground-glass opacities → consolidation → organizing pneumonia/fibrosis
• Complications: Pleural effusions (uncommon), pneumothorax (barotrauma in ventilated patients), secondary bacterial pneumonia (lobar consolidation)

5. Critical Care

Question: A 58-year-old woman with COVID-19 pneumonia is on CPAP with FiO2 60% but SpO2 remains 88%. Respiratory rate 35/min, appearing fatigued. What are your management options?

Answer:

• Intubation and mechanical ventilation - patient is failing CPAP (refractory hypoxemia, fatigue, high RR)
• Lung-protective ventilation strategy:
  • Low tidal volume (6 mL/kg ideal body weight)
  • PEEP 10-15 cmH2O (titrate to oxygenation and compliance)
  • Target plateau pressure less than 30 cmH2O
  • Permissive hypercapnia (pH > 7.20)
• Prone positioning (intubated proning) - ≥12-16 hours daily (proven mortality benefit in moderate-severe ARDS)
• Ensure optimized medical therapy:
  • Dexamethasone 6 mg daily
  • Consider tocilizumab if not already given
  • Therapeutic anticoagulation if not contraindicated (high D-dimer, high suspicion of PE)
• Rescue therapies if refractory: Recruitment maneuvers, neuromuscular blockade, inhaled pulmonary vasodilators, consider ECMO referral (selected patients)

Viva Voce Points

Topic: COVID-19 Immunology and Vaccination

Examiner: Can you explain the different types of COVID-19 vaccines?

Answer:

• mRNA vaccines (Pfizer-BioNTech, Moderna):

  • Lipid nanoparticles contain mRNA encoding the SARS-CoV-2 Spike protein
  • After injection, muscle cells take up the nanoparticles
  • Ribosomes translate the mRNA, producing Spike protein
  • Spike protein displayed on cell surface and secreted
  • Immune system recognizes Spike as foreign → B cells produce neutralizing antibodies, T cells provide cellular immunity
  • mRNA degraded within days (does NOT integrate into genome)
  • Highly effective, rapid to manufacture, but requires ultra-cold storage

• Viral vector vaccines (AstraZeneca, Janssen):

  • Replication-deficient adenovirus (chimpanzee adenovirus for AstraZeneca, human adenovirus 26 for Janssen) genetically modified to carry the Spike gene
  • Adenovirus infects cells, delivers Spike gene to nucleus
  • Cells produce Spike protein → immune response
  • Cannot replicate (non-replicating vector)
  • Cheaper, easier storage, but rare risk of VITT

• Protein subunit vaccines (Novavax):

  • Recombinant Spike protein produced in insect cells, assembled into nanoparticles
  • Given with adjuvant (Matrix-M) to enhance immune response
  • Traditional vaccine approach
  • Very safe, but requires adjuvant

Examiner: What is the rare complication associated with viral vector vaccines?

Answer: Vaccine-Induced Thrombotic Thrombocytopenia (VITT), also called Thrombosis with Thrombocytopenia Syndrome (TTS). Occurs approximately 5-30 days after vaccination (typically first dose) with an incidence of roughly 1 in 50,000-100,000 doses. It presents with unusual thromboses (cerebral venous sinus thrombosis, splanchnic vein thrombosis) combined with thrombocytopenia. The mechanism is similar to heparin-induced thrombocytopenia (HIT): antibodies against platelet factor 4 (PF4) cause platelet activation and consumption, leading to both thrombosis and thrombocytopenia. Diagnosis requires high index of suspicion (headache, abdominal pain, leg pain/swelling 5-30 days post-vaccine), testing for anti-PF4 antibodies. Treatment involves IVIG and non-heparin anticoagulation (e.g., argatroban, fondaparinux). Heparin is contraindicated.

Topic: COVID-19 Pathophysiology

Examiner: Why does COVID-19 cause thrombosis?

Answer: COVID-19 induces a prothrombotic state through multiple mechanisms, termed "immunothrombosis":

1. Endothelial injury and dysfunction:

   • Direct viral infection of endothelial cells (ACE2+)
   • Endotheliitis with inflammatory infiltrate
   • Loss of antithrombotic endothelial properties
   • Increased tissue factor expression → coagulation cascade activation

2. Inflammatory cytokines:

   • IL-6, IL-1β, TNF-α promote procoagulant state
   • Upregulate tissue factor and PAI-1 (plasminogen activator inhibitor-1)

3. Platelet activation:

   • Direct viral interaction with platelets
   • Thrombin generation
   • Platelet aggregation and degranulation

4. Neutrophil extracellular traps (NETs):

   • Activated neutrophils release DNA, histones, and proteases
   • NETs provide scaffold for thrombus formation
   • Directly injure endothelium

5. Complement activation:

   • Alternative pathway activation
   • C5a promotes inflammatory and procoagulant responses
   • Membrane attack complex damages endothelium

6. Hyperviscosity:

   • Elevated fibrinogen, Factor VIII, von Willebrand factor
   • Dehydration, hypoxia-induced polycythemia

7. Immobility: Hospitalized patients have reduced mobility, contributing to venous stasis

Clinical consequences: High rates of VTE (DVT, PE), arterial thrombosis (stroke, MI), microvascular thrombosis in lungs and other organs, DIC in severe cases. This necessitates prophylactic anticoagulation for all hospitalized patients.

Topic: COVID-19 Treatment Evolution

Examiner: What did the RECOVERY trial teach us about COVID-19 treatment?

Answer: The RECOVERY trial was the world's largest randomized controlled trial in COVID-19, conducted in the UK, enrolling over 40,000 hospitalized patients. It was an adaptive platform trial, testing multiple interventions. Key findings:

1. Dexamethasone (June 2020): First and most important finding

   • Reduced mortality by 1/3 in ventilated patients, 1/5 in patients on oxygen
   • NO benefit in non-hypoxemic patients
   • Established corticosteroids as cornerstone of severe COVID-19 treatment
   • Changed practice globally within weeks

2. Hydroxychloroquine (June 2020): NO benefit

   • Stopped early for futility
   • Debunked early claims from low-quality studies

3. Azithromycin (December 2020): NO benefit

   • No improvement in mortality, hospital stay, or progression to ventilation
   • Avoid routine antibiotics in COVID-19

4. Tocilizumab (February 2021): Mortality benefit when added to dexamethasone

   • 4% absolute mortality reduction in hypoxemic patients
   • Reduced progression to mechanical ventilation
   • Established IL-6 blockade as second-line therapy

5. Convalescent plasma: NO benefit (stopped)

6. Colchicine: NO benefit (stopped)

Impact: RECOVERY trial shaped global treatment protocols, demonstrating the power of large, pragmatic, adaptive RCTs during a pandemic. It saved hundreds of thousands of lives through rapid, definitive evidence generation.

---

16. References

Primary Sources

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-793. PMID: 32648899

2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. PMID: 33024307

3. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020;173(5):362-367. PMID: 32491919

4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239-1242. PMID: 32091533

5. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407. PMID: 32362390

6. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. PMID: 32678530

7. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. PMID: 33933206

8. Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-537. PMID: 33876268

9. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-1302. PMID: 35753318

10. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. PMID: 32015507

11. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet. 2021;397(10285):1603-1605. PMID: 33865497

12. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021;174(1):69-79. PMID: 32941052

13. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. PMID: 32142651

14. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. J Pathol. 2004;203(2):631-637. PMID: 15141377

15. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-582. PMID: 32150748

16. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679-686. PMID: 35042229

17. Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706-714. PMID: 35062016

18. Yamada S, Tsuji Y, Nakamura E. Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. Int J Mol Sci. 2022;23(5):2338. PMID: 35328761

19. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412-420. PMID: 33277344

20. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. PMID: 34308300

21. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. PMID: 33753937

22. Couzin-Frankel J. The mystery of the pandemic's 'happy hypoxia'. Science. 2020;368(6490):455-456. PMID: 32355007

23. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. Am J Respir Crit Care Med. 2020;202(3):356-360. PMID: 32539537

24. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. PMID: 32192578

25. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474. PMID: 32303591

26. Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9(12):1387-1395. PMID: 34425070

27. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-1329. PMID: 32306492

28. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49. PMID: 32665858

29. WHO COVID-19 Dashboard. Accessed January 2026. https://covid19.who.int

30. Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613(7942):130-137. PMID: 36517599

31. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19(11):e1004107. PMID: 36332992

32. O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140-145. PMID: 33137809

33. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346. PMID: 32214079

34. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-320. PMID: 32846427

35. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. PMID: 32640463

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and latest evidence. Always consult appropriate specialists and follow local guidelines.